These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28480682)

  • 1. Adherence and Characteristics of HIV Post-Exposure Prophylaxis for a Population in Tel Aviv of Men who have Sex with Men.
    Oz N; Alon D; Stein GY; Turner D
    Isr Med Assoc J; 2017 Apr; 19(4):257-261. PubMed ID: 28480682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
    Leal L; León A; Torres B; Inciarte A; Lucero C; Mallolas J; Laguno M; Martínez-Rebollar M; González-Cordón A; Manzardo C; Rojas J; Pich J; Arnaiz JA; Gatell JM; García F;
    J Antimicrob Chemother; 2016 Jul; 71(7):1987-93. PubMed ID: 26994089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
    Leal L; León A; Torres B; Inciarte A; Lucero C; Mallolas J; Laguno M; Martínez-Rebollar M; González-Cordón A; Manzardo C; Rojas J; Pich J; Arnaiz JA; Gatell JM; García F;
    J Antimicrob Chemother; 2016 Jul; 71(7):1982-6. PubMed ID: 26994091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men.
    Foster R; McAllister J; Read TR; Pierce AB; Richardson R; McNulty A; Carr A
    Clin Infect Dis; 2015 Oct; 61(8):1336-41. PubMed ID: 26123937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-exposure prophylaxis for HIV infection in sexual assault victims.
    Inciarte A; Leal L; Masfarre L; Gonzalez E; Diaz-Brito V; Lucero C; Garcia-Pindado J; León A; García F;
    HIV Med; 2020 Jan; 21(1):43-52. PubMed ID: 31603619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To prescribe, or not to prescribe: decision making in HIV-1 post-exposure prophylaxis.
    Scholten M; Suárez I; Platten M; Kümmerle T; Jung N; Wyen C; Ernst A; Horn C; Burst V; Suárez V; Rybniker J; Fätkenheuer G; Lehmann C
    HIV Med; 2018 Oct; 19(9):645-653. PubMed ID: 29993176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High HIV incidence in men who have sex with men attending for postexposure prophylaxis: a service evaluation.
    Whitlock G; McCormack C; Fearnley J; McOwan A
    Sex Transm Infect; 2017 May; 93(3):214-216. PubMed ID: 27412954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicentre RCT and economic evaluation of a psychological intervention together with a leaflet to reduce risk behaviour amongst men who have sex with men (MSM) prescribed post-exposure prophylaxis for HIV following sexual exposure (PEPSE): a protocol.
    Llewellyn C; Abraham C; Miners A; Smith H; Pollard A; Benn P; Fisher M
    BMC Infect Dis; 2012 Mar; 12():70. PubMed ID: 22440090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant intolerability of efavirenz in HIV occupational postexposure prophylaxis.
    Wiboonchutikul S; Thientong V; Suttha P; Kowadisaiburana B; Manosuthi W
    J Hosp Infect; 2016 Apr; 92(4):372-7. PubMed ID: 26876748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-exposure prophylaxis use and recurrent exposure to HIV among men who have sex with men who use crystal methamphetamine.
    Oldenburg CE; Jain S; Mayer KH; Mimiaga MJ
    Drug Alcohol Depend; 2015 Jan; 146():75-80. PubMed ID: 25482500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HIV post exposure prophylaxis therapy - the experience of two major AIDS centers].
    Elbirt D; Levy I; Asher I; Mahlev-Guri K; Rosenberg-Bezalet S; Litachevsky S; Radian-Sade S; Sthoeger Z
    Harefuah; 2013 Apr; 152(4):224-9, 246. PubMed ID: 23844525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
    Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B;
    AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of HIV Post-Exposure Prophylaxis Among Men Who Have Sex With Men in Shenzhen, China: A Serial Cross-Sectional Study.
    Wang Y; Liu S; Zhang Y; Tan W; Xie W; Gan Y; Zheng C; Li H; Yang Z; Jiang L; Chen L; Zhao J
    AIDS Behav; 2022 Oct; 26(10):3231-3241. PubMed ID: 35380286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
    Lorente N; Fugon L; Carrieri MP; Andreo C; Le Gall JM; Cook E; Aboulker JP; Capitant C; Molina JM; Spire B
    AIDS Care; 2012; 24(4):468-77. PubMed ID: 22085083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Danish PEP Registry: Experience with the use of post-exposure prophylaxis following blood exposure to HIV from 1999-2012.
    Lunding S; Katzenstein TL; Kronborg G; Storgaard M; Pedersen C; Mørn B; Lindberg JÅ; Kronborg TM; Jensen J
    Infect Dis (Lond); 2016; 48(3):195-200. PubMed ID: 26529586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences of HIV postexposure prophylaxis (PEP) among highly exposed men who have sex with men (MSM).
    Palich R; Martin-Blondel G; Cuzin L; Le Talec JY; Boyer P; Massip P; Delobel P
    Sex Transm Infect; 2017 Nov; 93(7):493-498. PubMed ID: 28739808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence, adverse drug reactions, and discontinuation associated with adverse drug reactions of HIV post-exposure prophylaxis: a meta-analysis based on cohort studies.
    Liu S; Yuan D; Zhou Y; Fu G; Wang B
    Ann Med; 2023; 55(2):2288309. PubMed ID: 38065681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does dropping day 5 PEP follow-up affect outcomes? An audit of HIV post-exposure prophylaxis at a central London sexual health clinic.
    O'Keeffe C; Nwokolo N; McOwan A; Whitlock G
    Int J STD AIDS; 2015 Jul; 26(8):590-2. PubMed ID: 25122580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel combination HIV prevention strategy: post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine-using men who have sex with men.
    Landovitz RJ; Fletcher JB; Inzhakova G; Lake JE; Shoptaw S; Reback CJ
    AIDS Patient Care STDS; 2012 Jun; 26(6):320-8. PubMed ID: 22680280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.